Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-01-11
2011-01-11
Romeo, David S (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S141100, C424S142100, C424S158100, C530S317000, C530S350000, C530S387300, C530S388100, C530S388150, C530S388240, C530S389100, C530S389200, C514S021100
Reexamination Certificate
active
07867496
ABSTRACT:
The disclosure relates to methods of ameliorating nephrotoxic side effects of immunosuppressive agents whose immunosuppressive activity is mediated via upregulation of TGF-β such as, for example, cyclosporine (CsA). The disclosure provides treatment modalities for use in patients that require immunosuppression, e.g., patients at risk of transplant rejection or having an autoimmune disease. In the methods of the invention, a TGF-β antagonist, e.g., an anti-TGF-β antibody, is administered to a patient treated with an immunosuppressive agent. Such a TGF-β antagonist is administered in a therapeutically effective amount sufficient to alleviate the nephrotoxic effects of the immunosuppressive agent without substantially interfering with immunosuppressive activity of the agent.
REFERENCES:
patent: 6492497 (2002-12-01), Thompson et al.
patent: 2003/0069248 (2003-04-01), Chakravarty et al.
patent: WO 2004/060362 (2004-07-01), None
International Search Report and Written Opinion for PCT/US2005/033942, mailed May 30, 2006 from the International Searching Authority of the European Patent Office.
Islam et al., “Effect of Anti-Transforming Growth Factor-β Antibodies in Cyclosporine-Induced Renal Dysfunction,” Kidney International, 59:498-506, (2001).
Khanna et al., “Anti-Transforming Growth Factor Antibody at Low but Not High Doses Limits Cyclosporine-Mediated Nephrotoxicity Without Altering Rat Cardiac Allograft Survival,” Circulation, 110:3822-3829 (2004).
Khanna et al., “Transforming Growth Factor (TGF)-β Mimics and Anti-TGF-β Antibody Abrogates the In Vivo Effects of Cyclosporine: Demonstration of a Direct Role of TGF-β in Immunosuppression and Nephrotoxicity of Cyclosporine,” Transplantation, 67:882-889 (1999).
Ling et al., “Therapeutic Role of TGF-β-Neutralizing Antibody in Mouse Cyclosporine A Nephropathy: Morphologic Improvement Associated with Functional Preservation,” J. Am. Soc. Nephrol., 14:377-388 (2003).
Ninova et al. “Acute Nephrotoxicity of Tacrolimus and Sirolimus in Renal Isografts: Differential Intragraft Expression of Transforming Growth Factor-β1 and α-Smooth Muscle Actin,” Transplantation, 78:338-344 (2004).
Shihab et al., “Sirolimus Increases Transforming Growth Factor-β1 Expression and Potentiates Chronic Cyclosporine Nephrotoxicity,” Kidney International, 65:1262-1271 (2004).
Xin et al., “Suppression of Cyclosporine A Nephrotoxicity In Vivo by Transforming Growth Factor β Receptor-Immunoglobulin G Chimeric Protein,” Transplantation, 77:1433-1442 (2004).
Khanna Ashwani K.
Ledbetter Steven
Finnegan Henderson Farabow Garrett & Dunner LLP
Genzyme Corporation
National Institutes of Health
Romeo David S
The MCW Research Foundation Inc.
LandOfFree
Use of TGF-β antagonists to limit nephrotoxicity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of TGF-β antagonists to limit nephrotoxicity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of TGF-β antagonists to limit nephrotoxicity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2691661